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in a median of 144 days. Grade II acute GvHD occurred in 3 of 8
engrafting patients. No patient developed extensive chronic
GvHD. Five patients did not survive; causes of death were graft
failure with viral infection in 3 children and viral infection in 2.
Seven children 58% are surviving for 6–43 months (median, 24
months) posttransplantation. All surviving children have shown
stabilization of disease progression. Children transplanted before
age 3 years have continued to gain developmental skills including
speech, albeit at a slower-than-normal pace. All children exhibit
some degree of autistic behavior but remain relatively calm and
happy without major sleep disturbances or aggressive behaviors.
Four of the surviving children are now over 4.5 years old, and all
appear to have higher neurocognitive functioning than untreated
Sanﬁlippo patients of similar age. We conclude that UCBT im-
proves the quality of life for patients with Sanﬁlippo syndrome.
Transplantation before age 2 years allows for continued cognitive
and developmental gains.
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REDUCED TOXICITY MYELOABLATIVE CONDITIONING REGIMEN FOR
CHILDREN WITH MARROW STEM CELL DEFECTS (MSCD) OR LEUKEMIA
Horn, B.1, Baxter-Lowe, L.A.1, McMillan, A.1, Quinn, M.1,
DeSantes, K.2, Cowan, M.1 1University of California San Francisco,
San Francisco, CA; 2University of Wisconsin, Madison, WI.
Two major problems with busulfan/cyclophosphamide-contain-
ing conditioning regimens for children are acute toxicities (mu-
cositis and VOD) and graft failure/rejection. We have prospec-
tively evaluated a conditioning regimen using targeted dosing of IV
busulfan, ﬂudarabine, and rabbit ATG for its toxicity and efﬁcacy.
Patients included 19 children receiving HLA-matched related or
unrelated transplantation for MSCD, including thalassemia, aplas-
tic anemia (AA), metabolic diseases, congenital neutropenia, and
primary immunodeﬁciencies (n 15), and leukemia/MDS (n 3).
The targeted average steady-state concentration (Css) of busulfan
was 600 ng/mL for the cases of MSCD and 900 ng/mL for the
cases of leukemia/MDS. Donors were well HLA-matched unre-
lated volunteers (n  11), unrelated cord blood (n  1), and
HLA-matched relatives (n  6). The most common toxicity was
mucositis, which developed in 1/3 of the patients. None of the
patients developed VOD. All patients showed marrow engraftment
by 28 days. However, 2 of 19 patients, 1 with AA and the other with
adrenoleukodystrophy, rejected the graft by 6 weeks posttransplan-
tation. Two additional patients, 1 with mannosidosis and 1 with
thalassemia, had graft failure 6 months posttransplantation. Three
of these 4 were recipients of matched unrelated donor marrow
grafts, and 1 received related bone marrow graft. Three of the 4
patients were successfully retransplanted using a TBI-containing
regimen. There were 2 deaths, 1 from a preexisting CMV infection
in a child with Wiskott-Aldrich syndrome and 1 from complica-
tions related to graft rejection. The long-term disease-free survival
was 89%  7%, with a median follow-up of 27 months (range,
4–41 months), including the patients that needed second trans-
plants. The durable engraftment rate was 80%. We established a
quantitative PCR assay using short-tandem repeats (STRs) to
monitor engraftment in blood and bone marrow in cell subsets
including CD3, CD19, CD14/15, and CD34. Full (n  6) or
partial (n  9) donor chimerism was achieved in 15 evaluable
patients. Neither the results of early engraftment studies ( 30
days) nor the percentasge of donor CD3 cells were predictive of
ultimate engraftment outcome. Five of 9 patients with durable
mixed chimerism had  50% donor CD3 cells from 123–420
days posttransplantation. These results indicate that substituting
ﬂudarabine for cyclophosphamide can reduce toxicity with respect
to both mucositis and VOD, but that alternative regimens need to
be developed to improve durable engraftment.
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LOW TRANSPLANT-RELATED MORTALITY AFTER STEM CELL TRANS-
PLANTATION WITH IV BUSULFAN-BASED CONDITIONING IN PEDIAT-
RIC PATIENTS
Bolotin, E., Cooper, L., Synold, T., Sweetman, R., Mao, J., Palmer, J.,
Rosenthal, J. City of Hope, Duarte, CA.
High-dose busulfan is widely used in allogeneic and autologous
marrow transplantation preparative regimens.We evaluated the safety
and toxicity of IV busulfan (Bu) in combination with variety of che-
motherapeutic agents, including cytoxan, cytoxanVP16, melphalan,
and TBIBuVP16, as preparative therapy for stem cell transplan-
tation in pediatric patients. The length of follow up study was 3–40.3
months. Twenty-ﬁve pediatric patients (a total of 30 transplantation
procedures) with hematologic malignancies (n  11), solid tumors
(n  6), and nonmalignant disorders (n  8) were evaluated. Six
patients underwent autologous transplantation (5 with tandem trans-
plantation), and 19 patients underwent HLA-matched sibling alloge-
neic transplantation. The sources of the stem cells were peripheral
stem cells in 21, bone marrow in 7, and cord blood in 2.
All but 2 patients engrafted. ANC 500 was achieved at day 10–25
(median, day 13), and platelets  20 109 were achieved at day
14–85 (median, day 24). Grade 3–4 liver toxicities were diagnosed
in 17.3% of all patients; grade 3–4 pulmonary toxicities, in 10.9%.
There was no mortality in the ﬁrst 100 days after transplantation.
Pharmakokinetic studies showed a wide variability of busulfan
levels. The mean AUCs achieved after administration of the initial
test dose was 848.0 (461.1–1300.4). Adjustment of the IV busulfan
dose was made in 7 patients (28%). All doses were increased.
Individualization of busulfan doses has been recommended to ob-
tain sufﬁcient dose intensity to achieve engraftment while avoiding
relapse and toxicity. Published data demonstrated that using the IV
formulation of busulfan reduces variability in busulfan levels in both
adult and pediatric patients. However, most of the studies evaluated
IV busulfan in combination with cytoxan. We found that IV busulfan
in pediatric patients is generally well tolerated in combination with
cytoxan, melphalan, TBI, VP-16, and ﬂudarabine.
SOLID TUMORS
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TARGETED RADIOTHERAPY TO THE SKELETON USING 166HO-DOTMP
WITH AUTOLOGOUS STEM CELL TRANSPLANTATION FOR PATIENTS
WITH BONE-ONLY METASTATIC BREAST CANCER
Champlin, R.E., Booser, D., Rondon, G., Williams, P.A., Wendt, R.,
Hortobagyi, G., Ueno, N., Podoloff, D. University of Texas M.D.
Anderson Cancer Center, Houston, TX.
The skeleton is the most frequent site of metastatic disease in breast
cancer. A subset of patients develop bone-dominant disease without
metastases to other organs. An attractive strategy is to utilize bone-
targeted radiotherapy. This study was designed to determine the
safety and preliminary efﬁcacy of 166Ho-DOTMP, which localizes to
bone, providing radiation to adjacent marrow and malignant cells.
The limiting toxicity is myelosuppression, which can be overcome by
autologous stem cell transplantation. We studied this strategy in
patients with breast cancer metastatic to conﬁned to the bone.
Treatment occurred between 1997 and 1999. Patients were eli-
gible if they were  65 years of age, had bone-only disease, had an
estrogen receptor–negative tumor, or had failed hormonal therapy.
A 30-mCi tracer dose was administered to assess targeting and to
calculate the therapeutic dose. The therapeutic dose was adminis-
tered in one of 2 dose levels, either 22 Gy (n  3) or 28 Gy (n 
3). Treatment was followed by autologous stem cell transplantation
when the ongoing radiation dose to marrow was  1 cGy/hour.
The 6 subjects received a median of 1548 mCi (range, 870–2065
mCi) of 166Ho DOTMP. There was selective uptake in the bone,
particularly in osteoblastic metastases; unbound drug was excreted
in the urine. The most common toxicities were mild nausea and
vomiting. None of the patients experienced grade  3 acute tox-
icity except for the expected profound myelosuppression. All pa-
tients had prompt hematologic recovery. Two patients developed
hemorrhagic cystitis at approximately 2 years following therapy,
which resolved in both cases. One of these patients also had GI
bleeding and pseudomembranous colitis unrelated to the 166Ho
DOTMP treatment. One patient developed MDS, but was found
to have a preexisting trisomy-8 by FISH analysis from the periph-
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eral blood stem cell product collected before treatment on this
study. Two patients achieved complete remission and remain pro-
gression-free more than 5 years after study entry. Four relapsed
and died of progressive disease; all recurred in extraosseous sites
with 2 also having disease in the bone marrow. Median time to
progression was 10 months.
We conclude that treatment with 166Ho DOTMP delivers tar-
geted radiotherapy to the skeleton with an acceptable toxicity
proﬁle. Two patients with bone-only metastases achieved sustained
complete responses. Further studies are warranted to evaluate this
strategy for treatment of bone metastases.
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TANDEM HIGH-DOSE CHEMOTHERAPY (HDC) WITH PERIPHERAL
BLOOD STEM CELL RESCUE (PBSCR) AS CONSOLIDATION THERAPY
FOR HIGH-RISK (PRIMARY UNRESECTABLE PELVIC TUMORS OR MET-
ASTATIC DISEASE) EWING’S SARCOMA PATIENTS
Burke, M.J., Kletzel, M., Jacobsohn, D.A., Duerst, R.E. Children’s
Memorial Hospital, Feinberg School of Medicine, Northwestern Univer-
sity, Chicago, IL.
Methods: Between 1985 and 2004, 14 patients with high-risk
Ewing’s sarcoma received induction chemotherapy, surgery, and
radiation therapy, with 8 of the 14 patients receiving tandem
transplantations. The median age at diagnosis was 14 years (range,
1–17 years) for the 8 patients receiving PBSCR and 9 years (range,
4–14 years) for the 6 patients who did not receive PBSCR. Of the
6 patients who did not receive a stem cell rescue, 5 had primary
pelvic tumors without metastatic disease, and 1 had a nonpelvic
primary tumor with bone metastases. Of the 8 patients who re-
ceived HDC and PBSCR, 6 patients had primary pelvic tumors (3
of them with pulmonary metastases), and the remaining 2 had
primary bone disease outside of the pelvis with bone metastases. Of
the 8 patients who received a transplant, 2 received chemotherapy
only before PBSCR, and 6 received chemotherapy and surgery
before transplantation. Three ablative regimens were used for the
8 patients. Six patients received tandem rescues. Rescue 1 included
etoposide (VP-16), 800 mg/m2/day for 3 days; carboplatin (CP),
667 mg/m2/day for 3 days; and cyclophoshamide (CTX), 1800
mg/m2/day for 2 days. Rescue 2 involved thiotepa (TT), 300
mg/m2/day for 3 days; CTX (n  1), melphalan/CTX (n  4), and
melphalan/TBI (n  1); VP-16, 800 mg/m2/day for 4 days; CTX,
1800 mg/m2/day for 3 days; total body irradiation (TBI), 200 cGy
BID for 3 days (n 1); melphalan, 60 mg/m2/day for 3 days; CTX,
500 mg/m2/day for 4 days (n  1). The median stem cell dose was
1.78  108 mnc/kg (range, 1.0  108 to 2.3  108 mnc/kg).
Results: The mean time to achieve ANC  500 was 13 days
(range, 7–17 days), and the mean time to achieve a platelet count
20K for 7 consecutive days unsupported was 23 days (range, 7–57
days). There were no toxic deaths in the 8 patients who received
PBSCR. Five of the 8 patients who received PBSCR are in com-
plete remission, with a median follow-up of 7.8 years (range,
36–118 months). Of the 6 patients who did not receive PBSCR, 3
continue in complete remission with a median follow-up of 10.5
years (range, 120–132 months). Conclusions: Our results suggest
that high-dose therapy with PBSCR is an effective and feasible
treatment for patients with high-risk Ewing’s sarcoma. A larger




CD133-POSITIVE HEMATOPOIETIC STEM CELLS “STEMNESS” GENES
CONTAIN MANY GENES MUTATED OR ABNORMALLY EXPRESSED IN
LEUKEMIA
Toren, A.1, Bielorai, B.1, Jacob-Hirsh, J.1, Fisher, T.1, Kreiser, D.1,
Zelikovsky, S.1, Givol, D.2, Itskovitz-Eldor, J.3, Rosenthal, E.1,
Amariglio, N.1, Rechavi, G.1 1Sheba Medical Center, Tel-Hashomer,
Israel; 2Weizmann Institute of Science, Rehovot, Israel; 3Rambam Med-
ical Center, Haifa, Israel.
Several groups have recently used microarray technology to
study the common characteristics of stem cells from different
tissues (“stemness”) and the typical features of stem cells from
various sources (“tissue speciﬁcity”). Most groups focused their
study on mice, used relatively small cDNA microarrays, and used
CD34 as the cell surface marker for hematopoietic stem cells
isolation. We studied HSC cells from cord blood (CB) and periph-
eral blood (PB)characterized by expression of the primitive CD133
antigen, and used the Affymetrix Human Hu133A oligonucleotide
arrays to study the gene expression proﬁle of these cells.
An unsupervised hierarchical clustering of 14,025 “valid” probe
sets showed a clear distinction between the CD133 cells repre-
senting the stem cell population and CD133 cells that represent
various stages of cell differentiation. Comparison of CD133 cells
isolated from CB and PB to CD133 cells identiﬁed 304 genes
that were up-regulated by at least 2-fold in CB and 218 genes in
PB. These genes were considered source-speciﬁc and possibly
relevant to the unique properties of CB- and PB-derived HSC. A
total of 244 genes were found to be up-regulated by at least 2-fold
in the CD133 cells of both CB and PB compared with the
CD133 cells. Comparison of these “stemness” genes to the lists
of “stemness” genes that were identiﬁed by 2 recent studies that
analyzed mainly murine HSC identiﬁed totals of 33 and 65 com-
mon genes. Twenty-four genes were common to another study
that analyzed human HSC.
Among these common “stemness” genes, we identiﬁed several
groups of genes that have an important role in hematopoiesis:
growth factor receptors, a group of transcription factors that in-
cludes several homeobox genes and TGF- target genes, genes
that have an important role in development, and genes involved in
cell growth. Among these 4 groups, we identiﬁed 16 “stemness”
genes (MPL, FLT3, HOXA9, MEIS 1, MLLT3, KIT, TIE,
GATA-2, HOXA5, HOXA10, HLF, MYCN, EVI1, MYB, FHL1,
and HMGA2) that are known to be mutated or abnormally regu-
lated in acute leukemias. It can be suggested that key hematopoi-
etic stemness machinery genes may lead to abnormal proliferation
and leukemia on mutation or change of expression.
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PLEIOTROPHIN IS A KEY SWITCH OF HUMAN MONOCYTES AND BONE
MARROW STEM CELLS INTO ENDOTHERLIAL-LIKE CELLS FOR ANGIO-
GENESIS IN TUMOR GROWTH
Chen, H.1, Zhu, D.1, Campbell, R.A.1, Pan-James, C.1, Wang, C.S.1,
Gordon, M.S.1,2, Bonavida, B.2, Berenson, J.R.1 1Institute for Myeloma
and Bone Cancer Research, West Hollywood, CA; 2UCLA School of
Medicine, Los Angeles, CA.
Multiple myeloma (MM) patients express pleiotrophin (PTN), a
secreted protein that binds CD138, and it is found at high levels in
the serum of MM patients. We have discovered a novel mechanism
leading to blood vessel formation by tumor cells. First, we puriﬁed
human monocytes (CD14) and cultured on collagen I, collagen
IV, ﬁbronectin, or laminin-coated dishes. The cells incubated on
collagen I (but not on the other 3 proteins) with mCSF  PTN
formed tube-like structures with positive staining for Flk-1. Com-
plex lines consisting of multiple rows of elongated Flk-1 cells in
contact with each other were found. In contrast, monocytes incu-
bated with only mCSF or on other substrates remained in sepa-
rated positions. We also cloned human monocytic THP-1 cells
with PTN sense or antisense whole sequencing DNA. We exam-
ined expression by RT-PCR of endothelial cell markers Flk-1,
Tie-2, and vWf and monocyte markers c-fms and CD68. THP-1
cells infected with PTN sense strand expressed high amounts of
Flk-1, Tie-2, and vWf similar to that found in human coronary
artery endothelial cells and lost expression of c-fms and CD68.
Next, we cultured THP1 monocytes with human myeloma
RPMI8226 cells in transwell cultures, serum derived from MM
patients with high serum levels of PTN, cell lines lacking PTN
expression, or normal controls lacking serum PTN. The THP-1
cells exposed to the MM cell line or MM serum showed expression
of endothelial markers. The expression of endothelial markers was
blocked by adding anti-PTN antibody. We also determined
whether PTN could also stimulate differentiation of bone marrow
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